Articles

The answer comes from a mediation analysis of the EMPA-REG OUTCOME Trial.

Higher score measuring severity of pain indicated elevated treatment failure risk.

Young patients with low BMIs, C-peptide levels, and significant symptoms at onset of diabetes at higher risk of undergoing rapid C-peptide decline.

Patients are not seeing the expected results because of medication adherence.

By Guest Writer David Kliff, Publisher, Diabetic Investor

As 2018 begins, my attention turns toward a look back at the year gone by and ahead to the year that’s starting. As always, my New Year will begin in that beautiful city by the bay at the JP Morgan Healthcare Conference. This is a conference I suspect will be one of the more interesting, and since I’ve attended nearly 20, that’s saying something. Lots is going on behind the scenes in our wacky world, and given the nature of JPM I suspect the veil of secrecy will be lifted.

With millions of possible drug combinations for treatment of diabetes, hypertension, hyperlipidemia and heart disease, new AI program offers more thorough analysis and options.

Getting type 2 diabetes at an early age increases risk for all diabetes complications, including death.

Why patients are not seeing results when it comes to adhering to treatment plans.

How best to decide whether to use one or a combination of the new treatments and individualize the treatment for your patients.

2017 was book-ended by the ADA: the new 2017 guidelines were the most popular article in January, and in December the 2018 guidelines took center stage. Please take a look back with us at everything that happened in between. We thank you for your readership this year, and look forward to sharing the important diabetes news of 2018.